Walethmade%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide

# Walethmade Bromide ## Overview Walethmade bromide is a non-barbiturate hypnotic and sedative agent. It is a bromide salt with central nervous system depressant properties. ## Primary Indications * Insomnia ## Adult Dosing * **Insomnia:** 50 mg to 100 mg orally at bedtime. * Maximum dose: 100 mg per dose. ## Pediatric Dosing * Dosing in pediatric patients is not established. Use with caution if considered. ## Dose Adjustments * **Hepatic Impairment:** Use with caution. Consider reduced dose. * **Renal Impairment:** Use with caution. Monitor for accumulation. * **Elderly:** Use with caution. Lower doses may be appropriate due to increased sensitivity. ## Contraindications * Hypersensitivity to walethmade bromide or other bromide salts. * Severe hepatic or renal impairment. * Severe respiratory depression. * Acute intermittent porphyria. ## Adverse Effects * **Common:** Drowsiness, dizziness, headache, ataxia, confusion, gastrointestinal upset. * **Serious:** Bromism (chronic toxicity from bromide accumulation), characterized by neurological (lethargy, stupor, psychosis, memory impairment), psychiatric, and dermatological symptoms (acneiform rash). Respiratory depression, paradoxical excitement, hypotension. ## Key Drug Interactions * **CNS Depressants (e.g., alcohol, opioids, benzodiazepines, other sedatives/hypnotics):** Additive CNS depression. Increased risk of sedation, respiratory depression. * **Drugs affecting hepatic metabolism (CYP450 inducers/inhibitors):** Potential for altered walethmade bromide levels, although its metabolism is not extensively characterized. ## Monitoring * Signs and symptoms of bromism, especially with prolonged use or in patients with impaired renal function. * Sedation and cognitive function. * Respiratory rate and depth. ## Clinical Pearls * Due to the risk of bromism, use should be limited to short-term treatment. * Tolerance may develop, necessitating dose escalation, which increases the risk of toxicity. * Avoid concurrent use with other CNS depressants. * Consider alternative agents for chronic insomnia management due to the potential for dependence and toxicity. *** *Disclaimer: This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant literature before making clinical decisions.*